Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Bindu Murthy, Bing He et al.|Clinical Pharmacology in Drug Development|2022Cited by 12
Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy ParticipantsSébastien Bihorel, Ihab Girgis, Shalabh Singhal et al.|Clinical Pharmacology in Drug Development|2020Cited by 6
THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTSShalabh Singhal, John Throup, Santanu Dutta et al.|Annals of the Rheumatic Diseases|2019Cited by 4
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participantsShalabh Singhal, John Throup, Ihab Girgis et al.|Expert Opinion on Investigational Drugs|2020Cited by 4